Danaher Corporation $DHR Shares Bought by Investors Research Corp

Investors Research Corp grew its position in shares of Danaher Corporation (NYSE:DHR) by 28,000.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 2,810 shares of the conglomerate’s stock after buying an additional 2,800 shares during the quarter. Investors Research Corp’s holdings in Danaher were worth $535,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Danaher by 303.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after purchasing an additional 186,584 shares during the period. SeaBridge Investment Advisors LLC purchased a new position in Danaher during the fourth quarter worth about $4,477,000. Legal & General Group Plc boosted its holdings in Danaher by 1.0% in the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock valued at $1,029,061,000 after purchasing an additional 43,169 shares during the last quarter. Whittier Trust Co. grew its stake in shares of Danaher by 12.2% in the 4th quarter. Whittier Trust Co. now owns 292,894 shares of the conglomerate’s stock valued at $69,296,000 after buying an additional 31,790 shares during the period. Finally, Annex Advisory Services LLC acquired a new stake in shares of Danaher during the 4th quarter worth approximately $3,466,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on DHR shares. UBS Group reduced their price target on shares of Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Evercore restated an “outperform” rating and issued a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $245.00 price objective on shares of Danaher in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Stock Down 0.6%

Shares of NYSE DHR opened at $206.23 on Thursday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $192.42 and its two-hundred day moving average is $193.36. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a market cap of $144.98 billion, a price-to-earnings ratio of 36.63, a PEG ratio of 2.58 and a beta of 0.78.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company’s revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.77 earnings per share. Research analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.